Three-year follow-up of serum 25-hydroxyvitamin D, parathyroid hormone, and bone mineral density in nursing home residents who had received 12 months of daily bread fortification with 125 μg of vitamin D3
© Mocanu and Vieth; licensee BioMed Central Ltd. 2013
Received: 15 February 2013
Accepted: 7 October 2013
Published: 11 October 2013
We conducted a single-arm clinical trial in institutionalized seniors, on the effects of high-dose vitamin D3-fortified bread daily intake (clinicaltrials.gov registration NCT00789503).
At 1 and 3 years after the dietary fortification was stopped, serum 25-hydroxyvitamin D (25(OH)D), parathyroid hormone (PTH) and bone mineral density were measured in 23 of the original study subjects, aged 60-82 years who had consumed bread buns (100 g) fortified with 320 mg elemental calcium and 125 μg (5,000 IU) vitamin D3 daily for one year.
At the end of the 1-year supplementation phase (receiving vitamin D3 fortified bread daily), mean (SD) serum 25(OH)D was 127.3 ± 37.8 nmol/L (baseline for this follow-up). At 1-year follow-up, the serum 25(OH)D was 64.9 ± 24.8 nmol/L (p = 0.001, vs. baseline); and at 3-year follow-up it was 28.0 ± 15.0 nmol/L (p = 0.001 vs. baseline). Serum PTH was 18.8 ± 15.6 pg/ml at baseline while at Year 3 it was 48.4 ± 18.4 pg/ml (p = 0.001 vs. baseline). Lumbar spine BMD did not change from baseline to Year 3. However, by Year 3, hip BMD had decreased (0.927 ± 0.130 g/cm2 vs. 0.907 ± 0.121 g/cm2, p = 0.024).
Vitamin D nutritional status exhibits a long half-life in the body, and a true steady-state plateau may not even be reached 1 year after a discontinuation in dose. Furthermore, once the need for vitamin D has been established, based on a low baseline serum 25(OH)D concentrations, the appropriate action is to maintain corrective vitamin D supplementation over the long term.
Clinical trial registration number: NCT00789503
KeywordsGeriatrics Cholecalciferol Osteoporosis Vitamin D deficiency Bread fortification
Older adults are particularly susceptible to vitamin D insufficiency  particularly in nursing homes . In Romania, serum 25-hydroxyvitamin D (25(OH)D) concentrations in institutionalized seniors were 28.5 ± 10.8 nmol/L , far below the minimum 50 nmol/L that the US Institutes of Medicine has set as the basis for its latest recommended dietary allowance (RDA) .
The serum 25(OH)D concentrations likely required to minimize the risk of falls and fractures has been estimated to be between 75 and 100 nmol/l . We previously provided evidence to support this recommendation by completing a single-arm clinical trial in which we provided institutionalized seniors with bread fortified each day with 125 μg (5,000 IU) of vitamin D3. This dietary protocol ensured that virtually all of the adults achieved serum 25(OH)D concentrations of at least 75 nmol/L. Here we report the long-term follow-up of study subjects at 1 and 3 years after discontinuing the clinical trial. During this time, the subjects have returned to their previous standard of health care, which did not provide a vitamin D supplement.
Subjects and methods
Study population and design
The single-arm clinical trial (clinicaltrials.gov registration NCT00789503) initially enrolled 45 patients (28 women and 17 men), 58 to 89 years of age (71 ± 6.9 years), all residing in a nursing home located in Iasi, Romania (Latitude 47°N) . At the end of the one-year supplementation protocol (consumption of bread buns fortified with 5,000 IU vitamin D3 per daily serving) , 33 patients were assessed by Dual-energy X-ray absorptiometry (DXA) (January 2005). Initial and final bone mineral density (BMD) data were available for 33 subjects. These patients were retested by DXA one and three years after the vitamin D protocol was discontinued (January 2006 and January 2008, respectively).
In the original study, all subjects received 125 μg (5,000 IU) vitamin D3/day and 800 mg calcium carbonate/day (320 mg of elemental calcium) for 1 yr.
Bone mineral density (BMD) of the lumbar spine and proximal femur was measured at baseline and after 12 months of vitamin D3 supplementation . The BMD measurements at the end of vitamin D3 supplementation were taken as the baseline values for this follow-up report (i.e. “baseline” refers to measures obtained at the end of 1 yr of vitamin D), and additional measurements were obtained after 12 and 36 months of follow-up study. Blood for serum calcium, 25(OH)D and serum PTH was obtained at baseline and at 1 and 3 years follow-up.
At the beginning of the original study, the 10-day food records obtained from the nursing home showed that the per-day vitamin D intake was 84 IU, while calcium intake was 717 mg. The participants did not take supplements of calcium, vitamin D, or both in the preceding 36 mo.
Both the intervention and follow-up studies were approved by the Human Investigation Review Committee at Grigore T. Popa University, and written informed consent was obtained from each subject.
Blood collection and analytical methods
Fasting blood samples were collected at baseline and after 1 and 3 years of follow-up study. Serum and plasma were kept frozen until analysis.
Serum calcium concentrations were measured by standard laboratory methods. Serum 25(OH)D concentrations were assayed by HPLC method  (results were validated through the DEQAS proficiency survey (http://www.deqas.org) for 25(OH)D, and the results were within the all-laboratory methods mean). Serum intact PTH was measured by an enzyme-amplified “two-step” sandwich-type immunoassay (DSL, Webster, Texas, USA) with an inter-assay CV ranging from 6.0 to 6.3% (normal range for adults 40-70 years of age, pg/ml). The BMD of the lumbar spine, femoral neck and trochanter were measured by dual energy x-ray absorbtiometry (Hologic, Delfi A and Delfi W). The calibration of bone densitometer was performed by scanning the European Spine Phantom. All measurements were performed by the same experienced technician.
Statistical analyses were performed using SPSS version 15.0 (SPSS Inc, Chicago). Data are expressed as mean ± SD. The distributions of all variables were tested with Kolmogorov-Smirnov tests. Descriptive statistics (mean and SD) were determined for all variables. Effects of the follow-up after the vitamin D protocol was completed were examined using the paired t-test versus the “baseline” values for each subject, which in the context of the present follow-up report are those values obtained at the end of the 1-yr intervention with vitamin D-fortified bread. A two-way repeated-measures ANOVA was conducted to explore the impact of sex and age on outcome variables (lumbar and hip BMD, concentrations of serum calcium, 25(OH)D, and PTH).
Characteristics of the population
Baseline characteristics of the patients having received 125 μg (5,000 IU) vitamin D 3 /day and 800 mg calcium carbonate/day (320 mg of elemental calcium) for 12 months (N = 23)
67.0 ± 5.2
69.1 ± 5.1
68.3 ± 5.6
81.5 ± 11.9
71.2 ± 10.2
76.3 ± 11.3
167.0 ± 4.3
154.0 ± 5.5
159.4 ± 7.3
29.3 ± 4.6
30.5 ± 4.2
30.0 ± 4.3
Vitamin D intake (μg/d)
2.1 ± 1.1
1.5 ± 0.9
1.7 ± 1.0
Calcium intake (mg/d)
938 ± 432
758 ± 341
780 ± 387
Measurements of serum 25-hydroxyvitamin D
Biochemical values and BMD changes before vitamin D bread consumption, at baseline of follow-up study (after 12 mo of vitamin D bread consumption) and after 12 and 36 months the supplementation with vitamin D was discontinued
Vitamin D bread consumption (-12 mo)
Baseline of follow-up study (0 month)
12 month follow-up
Serum calcium (Normal: 2.15-2.55 mmol/L)
2.30 ± 0.14
2.31 ± 0.13
2.26 ± 0.13
2.29 ± 0.15
Serum 25(OH)D (Sufficiency: 50-125 nmol/l)
29.8 ± 9.3
127.3 ± 37.8
64.9 ± 24.8
28.0 ± 15.0
Serum PTH (Normal: 16-62 pg/ml)
60.2 ± 42.6
18.8 ± 15.6
46.7 ± 21.2
48.4 ± 18.4
Lumbar spine BMD (g/cm2)
0.825 ± 0.113
0.858 ± 0.134
0.855 ± 0.146
0.867 ± 0.142
Total hip BMD (g/cm2)
0.736 ± 0.128
0.927 ± 0.130
0.913 ± 0.130
0.907 ± 0.121
Measurements of serum calcium and PTH
There were no significant differences in serum calcium concentrations at baseline versus 12 and 36 month follow-up (Table 2). Compared to the end-of clinical trial, PTH concentrations significantly increased by 12 months of follow-up (p = 0.0001) and by 36 months (p = 0.0001) but remained within the reference range. No treatment-related adverse events were observed during follow-up.
Bone mineral density measurements
Upon withdrawal of vitamin D3 (125 μg) supplementation, there were no significant differences in the mean percentages of change in lumbar spine; the mean percentages of change from baseline in lumbar spine BMD at 1-year follow-up was –0.31% and at 3-year follow-up was 1.03%. Statistically significant changes from baseline were noticed in hip BMD (Table 2); the mean relative change from baseline in hip BMD at 1-year follow-up was -1.52% and at 3-year follow-up was -1.99%.
Corrective action was not implemented after the original clinical trial was completed because the study subjects returned to their standard of care. Until the end of this follow-up, there was no compelling reason to provide more vitamin D. Although it was reassuring that at follow-up Year 1, the serum 25(OH)D was appropriate for the group, the data at follow-up Year 3 show that 25(OH)D had not established its new plateau. Previous studies suggests that when vitamin D supplementation is stopped, the serum 25(OH)D concentrations exhibit an apparent half-life of two months . However, the decline in serum 25(OH)D observed here exceeded 1 year (i.e. the decline exceeded six of the presumptive 2-month half-life); therefore, the apparent half life can be substantially longer than what has been previously estimated. One reason for a longer apparent half-life of the decline in serum 25(OH)D, compared to a tracer 25(OH)D compound, is because firstly, unmetabolised vitamin D is released from tissue stores built up during vitamin D supplementation, and secondly, there is a background of newly acquired vitamin D from the environment or diet that continues to be generate 25(OH)D.
At one year after the end of the clinical trial, the group as a whole met the 50 nmol/L criterion for serum 25(OH)D as recently established by US Institute of Medicine. While this was apparently reassuring, the further decline in 25(OH)D shown here emphasizes the need for sustained awareness and monitoring of vitamin D status in nursing home residents. Follow-up reports after discontinuation of vitamin D and calcium supplementation are sparse. One report of a similar population that was provided lower doses of vitamin D, showed that bone turnover markers had returned to baseline by two years after discontinuation, but serum 25(OH)D concentrations were not reported .
The present report is to our knowledge the longest follow-up after discontinuation of vitamin D, and it does show a sustained biochemical benefit to the one-year point, in that the serum 25(OH)D exceeded 50 nmol/L. However, by follow-up Year 3, the benefits of vitamin D fortification, were essentially gone. At follow-up Year 1, PTH had increased significantly from the end-of-vitamin D baseline. At follow-up Year 3, there was evidence that bone loss had progressed at the hip, but since there was no reference group in this study, the bone loss may reflect the normal age-related decline. The strength of this study is in its 3-yr characterization of the progression of the decline in 25(OH)D in older adults who had before-hand, received enough vitamin D to achieve 25(OH)D concentrations that most would consider to be in the optimal range. Among the weaknesses of this work is the lack of a reference group against which to compare the variables studied.
In retrospect, it is unfortunate that the serum 25(OH)D concentrations eventually returned to the osteomalacic levels present before the subjects initially entered the bread-fortification clinical trial. Lessons learned here are, firstly, that vitamin D nutritional status exhibits a long half-life in the body, whereby follow-up testing even at 1 year after a change in dose may not reflect a true plateau (i.e. steady-state) value; and secondly, that when a need for nutrient is established, even if this recognition is as part of a research protocol, then the appropriate action is to institute corrective measures beyond the extent of the research protocol.
The authors wish to thank to Professor Corina Galesanu for her valuable review of the results and suggestions, and to technician Valentin Zaharia for performing the DXA scans.
- Harris SS, Soteriades E, Coolidge JA, Mudgal S, Dawson-Hughes B: Vitamin D insufficiency and hyperparathyroidism in a low income, multiracial, elderly population. J Clin Endocrinol Metab. 2000, 85 (11): 4125-4130. 10.1210/jc.85.11.4125.PubMedGoogle Scholar
- Meyer HE, Smedshaug GB, Kvaavik E, Falch JA, Tverdal A, Pedersen JI: Can vitamin D supplementation reduce the risk of fracture in the elderly? A randomized controlled trial. J Bone Miner Res. 2002, 17 (4): 709-715. 10.1359/jbmr.2002.17.4.709.View ArticlePubMedGoogle Scholar
- Mocanu V, Stitt PA, Costan AR, Voroniuc O, Zbranca E, Luca V, Vieth R: Long-term effects of giving nursing home residents bread fortified with 125 microg (5000 IU) vitamin D(3) per daily serving. Am J Clin Nutr. 2009, 89 (4): 1132-1137. 10.3945/ajcn.2008.26890.View ArticlePubMedGoogle Scholar
- US Institute of Medicine: Dietary Reference Intakes for Calcium and Vittamin D. 2011, Washington, DC: National Academy PressGoogle Scholar
- Holick MF: Optimal vitamin D status for the prevention and treatment of osteoporosis. Drugs Aging. 2007, 24 (12): 1017-1029. 10.2165/00002512-200724120-00005.View ArticlePubMedGoogle Scholar
- Olkowski AA, Aranda-Osorio G, McKinnon J: Rapid HPLC method for measurement of vitamin D3 and 25(OH)D3 in blood plasma. Int J Vitam Nutr Res. 2003, 73 (1): 15-18. 10.1024/0300-98184.108.40.206.View ArticlePubMedGoogle Scholar
- Vieth R: The Pharmacology of Vitamin D. Vitamin D. Edited by: Feldman D, Pike JW, Adams JS. 2011, New York: Academic, 1041-1066. Third EditionView ArticleGoogle Scholar
- Dawson-Hughes B, Harris SS, Krall EA, Dallal GE: Effect of withdrawal of calcium and vitamin D supplements on bone mass in elderly men and women. Am J Clin Nutr. 2000, 72 (3): 745-750.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.